• 1. An integrated cathode and solid electrolyte via in situ polymerization with significantly reduced interface resistance?
  Jialiang Yuan,Ran Dong,Yuan Li,Yang Liu,Zhuo Zheng,Yuxia Liu,Yan Sun,Benhe Zhong,Zhenguo Wu,Xiaodong Guo Chem. Commun., 2021,57, 13004-13007
• 2. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068
• 3. An analysis of the WTC fires using CIB correlations and simple modeling
  JGQuintiere
• 4. An assessment of strategies for the development of solid-state adsorbents for vehicular hydrogen storage
  Mark D. Allendorf,Alauddin Ahmed,Tom Autrey,Jeffrey Camp,Eun Seon Cho,Maciej Haranczyk,Abhi Karkamkar,Di-Jia Liu,Katie R. Meihaus,Iffat H. Nayyar,Roman Nazarov,Donald J. Siegel,Vitalie Stavila,Jeffrey J. Urban,Srimukh Prasad Veccham,Brandon C. Wood Energy Environ. Sci., 2018,11, 2784-2812
• 5. Alt-proteins: A promising future

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Amphetamines and derivatives
• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Phenethylamines Amphetamines and derivatives
• Solvents and Organic Chemicals Organic Compounds Acids/Esters

Introduction to (3R)-3-(tert-butoxycarbonylamino)-4-phenyl-butanoic Acid (CAS No. 101555-61-7)

(3R)-3-(tert-butoxycarbonylamino)-4-phenyl-butanoic acid is a significant compound in the field of pharmaceutical chemistry, characterized by its complex structural framework and versatile applications. This compound, identified by the CAS number 101555-61-7, has garnered attention due to its role as a crucial intermediate in the synthesis of various bioactive molecules. The presence of a chiral center at the third carbon atom and the protective group tert-butoxycarbonyl (Boc) makes it particularly valuable in the development of enantiomerically pure pharmaceuticals.

The structural motif of (3R)-3-(tert-butoxycarbonylamino)-4-phenyl-butanoic acid consists of a four-carbon chain with an amine functional group at the third position and a phenyl ring at the fourth position. The Boc group, attached to the amine, serves as an essential protecting group that prevents unwanted side reactions during synthetic processes. This protection is crucial in multi-step syntheses where selective functionalization is required.

In recent years, there has been a growing interest in the development of chiral auxiliaries and ligands for asymmetric synthesis. The enantiomeric purity of pharmaceuticals is critical, as even minor differences in stereochemistry can significantly impact their biological activity and pharmacokinetic properties. The synthesis of (3R)-3-(tert-butoxycarbonylamino)-4-phenyl-butanoic acid exemplifies the importance of stereoselective methods in modern drug discovery.

Recent advancements in catalytic asymmetric transformations have enabled more efficient and scalable production of chiral intermediates like (3R)-3-(tert-butoxycarbonylamino)-4-phenyl-butanoic acid. Transition metal-catalyzed reactions, such as those involving palladium or rhodium complexes, have been particularly effective in achieving high enantiomeric excesses. These methods not only improve yield but also reduce the environmental impact by minimizing waste and energy consumption.

The utility of (3R)-3-(tert-butoxycarbonylamino)-4-phenyl-butanoic acid extends beyond its role as a synthetic intermediate. It has been employed in the development of novel therapeutic agents targeting various diseases. For instance, derivatives of this compound have shown promise in the treatment of neurological disorders due to their ability to interact with specific neurotransmitter receptors. The phenyl ring, in particular, can be modified to enhance binding affinity and selectivity.

The Boc group on the amine can be removed under mild acidic conditions, allowing for further functionalization of the molecule. This reactivity makes (3R)-3-(tert-butoxycarbonylamino)-4-phenyl-butanoic acid a versatile building block for constructing more complex structures. Researchers have leveraged this property to develop novel peptidomimetics and other bioactive molecules that mimic the structure and function of natural peptides.

The synthesis of chiral compounds like (3R)-3-(tert-butoxycarbonylamino)-4-phenyl-butanoic acid also involves considerations of green chemistry principles. Solvent selection, catalyst recovery, and waste management are critical factors that influence the sustainability of synthetic routes. Recent studies have focused on replacing traditional organic solvents with more environmentally friendly alternatives, such as water or biodegradable solvents, without compromising yield or enantiomeric purity.

In conclusion, (3R)-3-(tert-butoxycarbonylamino)-4-phenyl-butanoic acid (CAS No. 101555-61-7) represents a significant advancement in pharmaceutical chemistry due to its structural complexity and broad applicability. Its role as an intermediate in synthesizing enantiomerically pure drugs underscores its importance in modern drug discovery. As research continues to evolve, new methodologies for its synthesis and applications will likely emerge, further solidifying its place as a cornerstone compound in medicinal chemistry.

• 1142-20-7(N-[(Benzyloxy)carbonyl]-L-alanine)
• 1155-64-2(H-Lys(Z)-OH)
• 1161-13-3(Z-Phe-OH)
• 1164-16-5(Z-Tyr-OH)
• 1148-11-4(Carbobenzoxyproline)
• 405-39-0(Z-Lys(Z)-OH)
• 1152-61-0(Z-Asp-OH)
• 1152-62-1(Z-Met-OH)
• 1155-62-0(N-Carbobenzoxy-L-glutamic acid)
• 1149-26-4(N-Cbz-L-valine)